CN111801422B - 基于乳酸克鲁维酵母产生保护性单价和多价亚单位疫苗的优化的宿主/载体系统 - Google Patents

基于乳酸克鲁维酵母产生保护性单价和多价亚单位疫苗的优化的宿主/载体系统 Download PDF

Info

Publication number
CN111801422B
CN111801422B CN201880083894.1A CN201880083894A CN111801422B CN 111801422 B CN111801422 B CN 111801422B CN 201880083894 A CN201880083894 A CN 201880083894A CN 111801422 B CN111801422 B CN 111801422B
Authority
CN
China
Prior art keywords
kluyveromyces lactis
strain
lac4
locus
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880083894.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN111801422A (zh
Inventor
H·C·赫里曼
M·贝伦斯
M·格鲍尔
K·布罗伊尼希
S-E·贝伦斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vero Vaccine Co ltd
Original Assignee
Vero Vaccine Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vero Vaccine Co ltd filed Critical Vero Vaccine Co ltd
Publication of CN111801422A publication Critical patent/CN111801422A/zh
Application granted granted Critical
Publication of CN111801422B publication Critical patent/CN111801422B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nutrition Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
CN201880083894.1A 2017-12-27 2018-12-19 基于乳酸克鲁维酵母产生保护性单价和多价亚单位疫苗的优化的宿主/载体系统 Active CN111801422B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102017012109.5 2017-12-27
DE102017012109.5A DE102017012109A1 (de) 2017-12-27 2017-12-27 Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis
PCT/DE2018/000379 WO2019129321A2 (de) 2017-12-27 2018-12-19 Optimiertes wirts-/vektorsystem zur erzeugung protektiver mono- und multivalenter subunit-vakzine auf basis der hefe kluyveromyces lactis

Publications (2)

Publication Number Publication Date
CN111801422A CN111801422A (zh) 2020-10-20
CN111801422B true CN111801422B (zh) 2024-06-14

Family

ID=65817691

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880083894.1A Active CN111801422B (zh) 2017-12-27 2018-12-19 基于乳酸克鲁维酵母产生保护性单价和多价亚单位疫苗的优化的宿主/载体系统

Country Status (18)

Country Link
US (2) US11905517B2 (enExample)
EP (1) EP3732293B1 (enExample)
JP (2) JP7782951B2 (enExample)
KR (1) KR102704217B1 (enExample)
CN (1) CN111801422B (enExample)
BR (1) BR112020013245A2 (enExample)
CA (1) CA3086598A1 (enExample)
DE (2) DE102017012109A1 (enExample)
DK (1) DK3732293T3 (enExample)
EA (1) EA202091435A1 (enExample)
ES (1) ES2990197T3 (enExample)
HR (1) HRP20241297T1 (enExample)
HU (1) HUE068358T2 (enExample)
MX (1) MX2020006846A (enExample)
PL (1) PL3732293T3 (enExample)
PT (1) PT3732293T (enExample)
WO (1) WO2019129321A2 (enExample)
ZA (1) ZA202003553B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4001417A1 (en) * 2020-11-13 2022-05-25 serYmun Yeast GmbH Yeast platform for the production of vaccines
CN119391747B (zh) * 2024-12-12 2025-11-18 华中农业大学 一种利用马克斯克鲁维酵母制备禽传染性法氏囊病vp2纳米颗粒口服疫苗的方法及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010054649A2 (de) * 2008-11-14 2010-05-20 Martin-Luther-Universität Halle-Wittenberg Verfahren zur oralen/mukosalen vakzinierung mittels rekombinanter hefen
WO2013107436A1 (de) * 2011-12-13 2013-07-25 Martin-Luther-Universität Halle-Wittenberg Vakzinierung mittels rekombinanter hefe durch erzeugung einer protektiven humoralen immunantwort gegen definierte antigene

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US7083787B2 (en) 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
CA2508957C (en) 2002-12-16 2015-11-17 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
BRPI0516356A (pt) 2004-10-18 2008-09-02 Globeimmune Inc terapia à base de levedura para infecções crÈnicas da hepatite c
SG169375A1 (en) 2006-02-02 2011-03-30 Globeimmune Inc Yeast-based vaccine for inducing an immune response
KR101781966B1 (ko) 2009-04-17 2017-09-27 글로브이뮨 암에 대한 병용 면역요법 조성물 및 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010054649A2 (de) * 2008-11-14 2010-05-20 Martin-Luther-Universität Halle-Wittenberg Verfahren zur oralen/mukosalen vakzinierung mittels rekombinanter hefen
WO2013107436A1 (de) * 2011-12-13 2013-07-25 Martin-Luther-Universität Halle-Wittenberg Vakzinierung mittels rekombinanter hefe durch erzeugung einer protektiven humoralen immunantwort gegen definierte antigene

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A novel, lactase-based selection and strain improvement strategy for recombinant protein expression in Kluyveromyces lactis;JORRIT-JAN KRIJGER ET AL;MICROBIAL CELL FACTORIES;第11卷(第1期);第1-12页 *
Comparison of secretion of a hepatitis C virus glycoprotein in Saccharomyces cerevisiae and Kluyveromyces lactis;MUSTILLI AC ET AL;RESEARCH IN MICROBIOLOGY;第150卷(第3期);第 179-187页 *
Divergent Evolution of the Transcriptional Network Controlled by Snf1-lnteracting Protein Sip4 in Budding Yeasts;CONSTANCE MEHLGARTEN ET AL;PLOS ONE;第10卷(第10期);第1-23页 *
Efficient secretion of human lysozyme from the yeast, Kluyveromyces lactis;TAKAKO IWATA ET AL;BIOTECHNOLOGY LETTERS;第26卷(第23期);第1803-1808页 *

Also Published As

Publication number Publication date
KR20200104367A (ko) 2020-09-03
KR102704217B1 (ko) 2024-09-09
WO2019129321A2 (de) 2019-07-04
CA3086598A1 (en) 2019-07-04
JP7782951B2 (ja) 2025-12-09
PT3732293T (pt) 2024-10-09
JP2021508496A (ja) 2021-03-11
MX2020006846A (es) 2020-11-06
DE112018006647A5 (de) 2020-10-01
HUE068358T2 (hu) 2024-12-28
ZA202003553B (en) 2021-06-30
ES2990197T3 (es) 2024-11-29
DK3732293T3 (da) 2024-09-23
DE102017012109A1 (de) 2019-06-27
CN111801422A (zh) 2020-10-20
WO2019129321A3 (de) 2019-09-12
EP3732293A2 (de) 2020-11-04
PL3732293T3 (pl) 2024-11-18
US20240102031A1 (en) 2024-03-28
US11905517B2 (en) 2024-02-20
BR112020013245A2 (pt) 2020-12-01
EA202091435A1 (ru) 2020-08-28
EP3732293B1 (de) 2024-07-03
JP2023166412A (ja) 2023-11-21
US20210230612A1 (en) 2021-07-29
HRP20241297T1 (hr) 2024-12-20
US12473562B2 (en) 2025-11-18

Similar Documents

Publication Publication Date Title
CN108070611B (zh) 植物碱基编辑方法
AU2018229561B2 (en) Recombinant adenoviruses and use thereof
CN108546712B (zh) 一种利用CRISPR/LbCpf1系统实现目的基因在植物中同源重组的方法
CN108138121B (zh) 用微生物高水平生产长链二羧酸
CN112375748B (zh) 基于水疱性口炎病毒载体的新型冠状病毒嵌合重组疫苗及其制备方法与应用
CN101918558B (zh) 流感的治疗及预防
CN108138154A (zh) 用于治疗黏多糖贮积病的腺相关病毒载体
KR102227976B1 (ko) Ｎａｄｈ 데히드로게나제가 불활성화된 효모 세포 및 그를 이용한 락테이트를 생산하는 방법
CN111088176B (zh) 产β-胡萝卜素的基因工程菌及其应用
CN111801422B (zh) 基于乳酸克鲁维酵母产生保护性单价和多价亚单位疫苗的优化的宿主/载体系统
KR102311681B1 (ko) 내산성을 갖는 효모 세포, 그를 이용하여 유기산을 생산하는 방법 및 상기 내산성 효모 세포를 생산하는 방법
CN110914414A (zh) 利用设计dna重组酶遗传改变基因组的方法与手段
CN109666647B (zh) 一种过表达igf-1的脐带间充质干细胞及其制备方法和应用
CN112175927B (zh) 一种碱基编辑工具及其用途
KR20140000711A (ko) 수크로스 이용에 있어서의 야로위아 리포라이티카에서의 사카로마이세스 세레비지애 suc2 유전자의 용도
DK2844759T3 (en) Vaccination by recombinant yeast by eliciting a protective humoral immune response against defined antigens
BRPI0616533A2 (pt) polinucleotìdeo isolado, fragmento de ácido nucléico isolado, construções de dna recombinante, plantas, sementes, células vegetais, tecidos vegetais, método de isolamento de fragmentos de ácidos nucléico, método de mapeamento de variações genéticas, método de cultivo molecular, plantas de milho, métodos de alteração do transporte de nitrogênio das plantas e variantes de hat de plantas alteradas
CN110846311A (zh) 利用抑制性tRNA系统制备PTC稳定细胞系及应用
KR102341583B1 (ko) 스플릿 인테인을 접목한 가용성 향상 이중 기능성 융합 태그를 이용한 재조합 섬유아세포 성장인자 수용체의 제조방법, 정제방법, 및 이의 용도
CN116457465A (zh) 用于基因组修饰的方法和组合物
KR102740600B1 (ko) 강력한 적응성 면역반응 유도 및 모체이행항체의 간섭을 극복하는 재조합 구제역 o형 바이러스 및 이를 포함하는 구제역 백신 조성물
KR102740602B1 (ko) 강력한 적응성 면역반응 유도 및 모체이행항체의 간섭을 극복하는 재조합 구제역 a형 바이러스 및 이를 포함하는 구제역 백신 조성물
CN111139210A (zh) 一种重组甲基营养菌和口服疫苗
KR20060003455A (ko) 티미딘 키나제 선발을 이용한 돼지 오제스키병 바이러스유전자 재조합 벡터 시스템
US20240042009A1 (en) Yeast-based expression of therapeutic proteins in vivo

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant